Immunome, Inc. (NASDAQ:IMNM) Stock Holdings Lessened by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in shares of Immunome, Inc. (NASDAQ:IMNM) by 15.7% in the third quarter, Holdings Channel.com reports. The institutional investor owned 43,865 shares of the company’s stock after selling 8,189 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Immunome were worth $641,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of IMNM. Marshall Wace LLP lifted its position in Immunome by 228.5% in the 2nd quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock valued at $20,731,000 after purchasing an additional 1,191,774 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Immunome by 217.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock valued at $6,469,000 after buying an additional 302,916 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after buying an additional 237,497 shares during the period. AXA S.A. bought a new position in Immunome in the 2nd quarter worth approximately $2,174,000. Finally, Bank of New York Mellon Corp bought a new position in Immunome in the 2nd quarter worth approximately $1,816,000. Institutional investors own 44.58% of the company’s stock.

Immunome Price Performance

IMNM opened at $10.97 on Friday. Immunome, Inc. has a 1-year low of $8.15 and a 1-year high of $30.96. The company has a market capitalization of $684.71 million, a price-to-earnings ratio of -1.35 and a beta of 1.83. The business has a 50 day moving average price of $12.14 and a two-hundred day moving average price of $13.35.

Analyst Ratings Changes

Several analysts have weighed in on the company. Stephens initiated coverage on Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Immunome in a report on Friday, October 25th. Finally, Piper Sandler reduced their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $28.83.

Insider Activity

In other Immunome news, CTO Philip Tsai purchased 21,000 shares of the firm’s stock in a transaction on Thursday, November 21st. The shares were purchased at an average price of $9.43 per share, for a total transaction of $198,030.00. Following the completion of the transaction, the chief technology officer now owns 21,000 shares in the company, valued at $198,030. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Robert Lechleider acquired 15,805 shares of the business’s stock in a transaction dated Thursday, November 21st. The shares were bought at an average price of $9.48 per share, with a total value of $149,831.40. Following the transaction, the insider now directly owns 15,805 shares in the company, valued at approximately $149,831.40. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 102,862 shares of company stock worth $978,045 over the last 90 days. 8.60% of the stock is currently owned by company insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.